SARS-CoV-2
Showing 26 - 50 of 246
Immunity to Infection in Healthy Participants and Cancer
Recruiting
- Influenza
- +3 more
- Biological sample collection
-
Tuebingen, Baden-Wuerttemberg, GermanyUniversity Hopsital Tuebingen
Mar 31, 2023
SARS-CoV-2 Trial in Herston (Glycovax-002)
Not yet recruiting
- SARS-CoV-2
- Glycovax-002
-
Herston, Queensland, AustraliaQ-Pharm Pty Ltd
Apr 3, 2023
Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test
Not yet recruiting
- SARS-CoV-2
- +3 more
- LumiraDx SARS-CoV-2 & Flu A/B
-
Cullman, AlabamaCullman Clinical Trials
Mar 16, 2023
SARS-CoV-2, COVID-19 Trial in Palo Alto, Seattle
Active, not recruiting
- SARS-CoV-2
- COVID-19
-
Palo Alto, California
- +1 more
Mar 13, 2023
SARS-CoV-2 Trial in Bengbu (SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine, Saline solution)
Recruiting
- SARS-CoV-2
- SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine
- Saline solution
-
Bengbu, Anhui, ChinaFirst Affiliated Hospital Bengbu Medical College
Feb 26, 2023
Covid Pandemic on the Patient in Need of an Intervention
Not yet recruiting
- Surgery Department, Hospital
- +4 more
- (no location specified)
Feb 20, 2023
LumiraDX SARS-CoV-2 Ag Ultra and LumiraDX SARS-CoV-2 & Flu A/B
Not yet recruiting
- SARS-CoV-2
- +4 more
- LumiraDx SARS-CoV-2 Ag Ultra
- LumiraDx SARS-CoV-2 & Flu A/B
-
DeLand, FloridaHillcrest Medical Research
Feb 6, 2023
SARS-CoV-2 Trial in Winston-Salem, San Antonio (ADM03820, Placebo)
Active, not recruiting
- SARS-CoV-2
- ADM03820
- Placebo
-
Winston-Salem, North Carolina
- +1 more
Feb 1, 2023
Severe Acute Respiratory Syndrome, Coronavirus, SARS-CoV-2 Trial in Belgium, Germany (CVnCoV Vaccine, Placebo)
Completed
- Severe Acute Respiratory Syndrome
- +3 more
- CVnCoV Vaccine
- Placebo
-
Ghent, Belgium
- +3 more
Apr 29, 2022
SARS-CoV-2, Influenza, RSV Trial in Australia, United Kingdom, United States (mRNA-1010, mRNA-1345, mRNA-1273.214)
Recruiting
- SARS-CoV-2
- +2 more
- mRNA-1010
- +4 more
-
DeLand, Florida
- +29 more
Jan 23, 2023
COVID-19, SARS-CoV-2 Trial in London (COVI-VAC)
Completed
- COVID-19
- SARS-CoV-2
- COVI-VAC
-
London, United KingdomHMR
Jan 11, 2023
SARS-CoV-2 Trial in United States (mRNA-1273.214, Placebo)
Recruiting
- SARS-CoV-2
- mRNA-1273.214
- Placebo
-
Madera, California
- +21 more
Jan 11, 2023
SARS-CoV-2 Trial (LVRNA009, 0.9%NaCl)
Not yet recruiting
- SARS-CoV-2
- LVRNA009
- 0.9%NaCl
- (no location specified)
Jan 11, 2023
SARS-CoV-2 Trial in United States (mRNA-1273, Placebo)
Recruiting
- SARS-CoV-2
- mRNA-1273
- +2 more
-
Banning, California
- +48 more
Jan 5, 2023
Coronavirus Disease 2019 With Point-of-Care Ultrasonography
Completed
- Coronavirus Infection
- +3 more
- Point-of-Care Ultrasonography (POCUS)
-
Minneapolis, Minnesota
- +1 more
Jan 2, 2023
SARS-CoV-2 Trial (SARS-CoV-2 mRNA Vaccine, Bivalent Low dose, SARS-CoV-2 mRNA Vaccine, Bivalent High dose, Placebo)
Recruiting
- SARS-CoV-2
- SARS-CoV-2 mRNA Vaccine, Bivalent Low dose
- +2 more
-
Bengbu, Anhui, ChinaFirst Affiliated Hospital Bengbu Medical College
Jan 3, 2023
SARS-CoV-2 Trial in Bengbu (SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA
Active, not recruiting
- SARS-CoV-2
- SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose
- +2 more
-
Bengbu, Anhui, ChinaFirst Affiliated Hospital Bengbu Medical College
Jan 3, 2023
SARS-CoV-2 Trial in Bengbu (COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose, COVID-19 Variant (Omicron BA.5) mRNA Vaccine
Recruiting
- SARS-CoV-2
- COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose
- +2 more
-
Bengbu, Anhui, ChinaFirst Affiliated Hospital Bengbu Medical College
Jan 3, 2023
COVID-19 Trial in Nanjing, Hangzhou (20 µg dose of SYS6006, 30 µg dose of SYS6006, Placebo)
Enrolling by invitation
- SARS-CoV-2
- 20 μg dose of SYS6006 ;30 μg dose of SYS6006
- Placebo
-
Nanjing, Jiangsu, China
- +1 more
Dec 20, 2022
COVID-19 Trial in Nanjing, Hangzhou (20 µg dose of SYS6006, 30 µg dose of SYS6006, Placebo)
Enrolling by invitation
- SARS-CoV-2
- 20 μg dose of SYS6006;30 μg dose of SYS6006
- Placebo
-
Nanjing, Jiangsu, China
- +1 more
Dec 20, 2022
Lung Transplant Recipient, SARS-CoV-2, Immunosuppression Trial (mRNA-1273 (Moderna COVID-19 vaccine))
Active, not recruiting
- Lung Transplant Recipient
- +2 more
- mRNA-1273 (Moderna COVID-19 vaccine)
-
Los Angeles, CaliforniaUCLA Clinical Translational Research Center
Dec 13, 2022
SARS-CoV-2 Trial (SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high
Not yet recruiting
- SARS-CoV-2
- SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose
- +2 more
- (no location specified)
Dec 1, 2022
SARS-CoV-2 Trial in United States (mRNA-1273.211, mRNA-1273, mRNA-1273.617.2)
Active, not recruiting
- SARS-CoV-2
- mRNA-1273.211
- +6 more
-
Sacramento, California
- +22 more
Nov 16, 2022